Zebrafish are making big waves in the field of cancer research. The effect has been widespread and continues to gain speed as more and more cancer researchers ride the wave of zebrafish biology. This has been largely due to the development of transgenic and xenograft models of cancer, which recapitulate many aspects of different human cancers including lymphoblastic T-cell leukemia, pancreatic cancer, melanoma and rhabdomyosarcoma. These models are already being utilized by academia and industry to search for genetic and chemical modifiers of cancer with success. The attention has been further stimulated by the amenability of zebrafish to pharmacological testing and the superior imaging properties of fish tissues that allow visualization of cancer progression and angiogenesis in live animals. This review summarizes the current zebrafish models of cancer and discusses their utility in human cancer research and future directions in the field.
Introduction
Zebrafish (Danio rerio) recently entered the stage as a promising model system to study human cancer (Table 1) . While it has been known for more than a century that teleost fish can develop tumors spontaneously or in response to various chemical carcinogens, it has not been until recently that this small creature has received so much attention by cancer researchers (Amatruda et al., 2002; Smolowitz et al., 2002; Stern and Zon, 2003; Berghmans et al., 2005a; Goessling et al., 2007a) . This is largely due to the development of fish lines harboring oncogenic transgenes and their amenability to genetic and pharmacological testing. Cancer progression in these animals recapitulates many aspects of human disease and opens the door for studies to identify genetic and chemical modifiers of cancer (Amatruda et al., 2002; Smolowitz et al., 2002; Stern and Zon, 2003; Berghmans et al., 2005a; Goessling et al., 2007a; Kari et al., 2007) . The attention has been further fueled by the development of xenograft models that allow the propagation and visualization of human cancer cells engrafted in optically transparent zebrafish (Haldi et al., 2005; Lee et al., 2005; Topczewska et al., 2006; Nicoli et al., 2007; Stoletov et al., 2007) . The integration of zebrafish genetics with the large tool chest of reagents available to study human cancer cells provides a powerful new vertebrate model to visualize and dissect the mechanisms that drive cancer formation, angiogenesis and metastasis. Finally, zebrafish have many attributes that cancer researchers find attractive. Compared to mice, zebrafish require minimal care and are cost effective to maintain in the laboratory (Amatruda et al., 2002; Smolowitz et al., 2002; Stern and Zon, 2003; Berghmans et al., 2005a; Goessling et al., 2007a; Kari et al., 2007) . A pair of adult fish produces several hundred fertilized eggs a week. The embryos develop externally and are transparent up to 1 month of age (Spitsbergen, 2007; Stoletov et al., 2007) . Adult, casper mutant (roy À/À ;nacre À/À ) animals are also available that remain transparent throughout life and are amenable to in vivo transplantation studies (Figure 1 ) (White et al., 2008) . The remarkable transparency of zebrafish tissues allows direct imaging of cancer progression including cell invasion, intravasation, extravasation and angiogenesis (Stoletov et al., 2007; White et al., 2008) . A complete sequence of the zebrafish genome is available and many human cancer genes are conserved structurally and functionally in zebrafish (http://www.ncbi.nlm.nih.gov/genome/guide/zebrafish). Zebrafish genetics is easily manipulated with numerous mutant or tissue-specific transgenic fish lines available (Amatruda et al., 2002; Smolowitz et al., 2002; Stern and Zon, 2003; Berghmans et al., 2005a; Beis and Stainier, 2006; Goessling et al., 2007a; Kari et al., 2007) . Zebrafish can also efficiently absorb small molecular weight compounds directly from water which makes this organism especially appealing for screening anticancer agents (Parng et al., 2002; Kari et al., 2007) .
Chemical mutagenesis
Chemical carcinogenesis was the first approach used to induce tumor formation in zebrafish. Water-soluble carcinogens can be added directly to the fish water and a number of chemical compounds that are carcinogenic in mammals induce tumor formation in zebrafish (Amatruda et al., 2002; Berghmans et al., 2005a; Goessling et al., 2007a, b) . Exposure to dimethylbenzanthracene, ethylnitrosourea, N-methyl-N-nitro-Nnitrosoguanidine, diethylnitrosamine results in a variety of tumors in zebrafish or medaka (Oryzias latipes) (Okihiro and Hinton, 1999; Beckwith et al., 2000; Spitsbergen et al., 2000a, b; Mizgireuv et al., 2004; Lam and Gong, 2006; Mizgireuv and Revskoy, 2006) . Most of the tumors that arise are hepatic but can also include other organs and tissues such as skin (papillomas), muscle (rhabdomyosarcomas and leiomyosarcomas), vasculature (hemangiosarcomas), testis (seminomas) and pancreas (pancreatic carcinomas) (Okihiro and Hinton, 1999; Beckwith et al., 2000; Spitsbergen et al., 2000a, b; Mizgireuv et al., 2004; Lam and Gong, 2006; Mizgireuv and Revskoy, 2006) . The basic histological and molecular characteristics of chemically induced neoplasia in zebrafish show significant similarity to human cancer including increased cell proliferation, atypical nuclear morphology and low degree of cell differentiation. Comparison of fish and human cancer gene signatures has also revealed significant resemblance between these species including genes involved in regulating the cell cycle, apoptosis and DNA repair (Lam and Gong, 2006; . Altogether, these findings suggest that the mechanisms driving carcinogenesis are highly conserved between mammals and zebrafish.
Chemical carcinogenesis has obvious advantages in studying tumor biology due to its technical simplicity and low cost. Tumor growth under these conditions represents a spontaneous tumor initiation within the proper tissue microenvironment. Disadvantages include low incidence of tumor development (B10%), late tumor onset and the tumors that develop are heterogenic in their genetic background and location (Table 1) . Also, tumor detection requires gross visible appearance of the tumor or histological examination of fixed zebrafish tissues. Recently, these obstacles were partially overcome by the generation of chemically induced zebrafish tumor cell lines that can be propagated and transplanted into syngenic animals (Mizgireuv and Revskoy, 2006) . These cell lines can be transplanted multiple times and maintain their relative growth and invasive properties in vivo. This area of zebrafish cancer biology needs to be further developed as establishment of zebrafish cancer cell lines would enable genetic profiling studies and imaging-based approaches to visualize tumor formation and invasion after labeling with fluorescent dyes or proteins. Fish cancer cell lines would also be instrumental in determining whether human oncogenes or treatment with anticancer agents directed against human cancer proteins impact fish cancer in a similar manner.
Mutant lines
The ability to perform large-scale genetic screens in zebrafish resulted in identification of several mutant (Her et al., 2003; Beis and Stainier, 2006; Wan et al., 2006; Kari et al., 2007; White et al., 2008) . This would allow direct visualization of tumor progression and distant metastases using standard brightfield and fluorescence microscopy.
Transgenic lines
Myc and TEL-AML1 leukemia models The power of zebrafish genetics allows one to express a gene of interest (for example, oncogene or mutant form of tumor suppressor) in a particular organ or tissue through the use of tissue-specific promoters. Additionally, the gene can be engineered to coexpress various forms of fluorescent proteins. This allows for direct selection of stable transgenic lines and in vivo monitoring of tumor progression by fluorescence microscopy. This strategy was pioneered by Langenau et al. (2003) when they overexpressed human c-myc under the control of the zebrafish rag2 promoter that drives T-cell expression. The resulting transgenic zRag2-EGFP-cMyc fish line showed rapid (21-42 days) onset of T-cell acute lymphoblastic leukemia. The GFP-c-myc cells were observed to rapidly infiltrate multiple organs and tissues that eventually led to animal lethality. In fact, these animals obtained cancer so rapidly that it precluded efficient maintenance of the fish line. Subsequently, the researchers improved their model by rendering c-myc expression conditionally using a Cre/ lox and heat shock promoter systems (Langenau et al., 2005a, b; Feng et al., 2007) . Additionally, tumor cells transplanted into irradiated recipient animals fully recapitulated the original cancer (Langenau et al., Feng et al., 2007) . The examination of molecular pathways activated in response to c-myc overexpression closely resembled the most common and most aggressive subclass of human leukemia, which is characterized by the coexpression of tal2 and lmo2 markers . In a separate study, the same group showed that irradiation or dexamethasone-induced apoptosis of fish leukemic cells is dependent on bcl-2 gene function that also operates in mammalian forms of leukemia (Langenau et al., 2005b) . Two independent studies used a similar approach to induce different subtypes of leukemia mediated by overexpression of the aberrant TEL-AML1 fusion protein using the ubiquitous b-actin promoter or overexpression of Notch using the rag2 promoter (Sabaawy et al., 2006; Chen et al., 2007) . Overexpression of TEL-AML1 led to the development of infiltrating B-lineage leukemia while rag2-mediated Notch overexpression resulted in T-cell leukemia. Both cancers also displayed similar properties with respect to mammals (Sabaawy et al., 2006; Chen et al., 2007) .
MYCN and kRASG12D solid tumors models Recently, tissue-specific oncogene overexpression was utilized in zebrafish for inducing not only blood borne neoplasia, but also various types of solid tissue cancers. MYCN overexpression, under the control of the myoD promoter, resulted in formation of pancreatic neuroendocrine tumors that originated from insulin-producing islet cells (Yang et al., 2004) . In another study, conditional overexpression of activated human Ras (kRASG12D), under the control of ubiquitous b-actin promoter, resulted in several tumor types including rhabdomyosarcoma, intestinal hyperplasia and malignant peripheral nerve sheath tumors (Patton et al., 2005) . These fish tumors displayed similar molecular characteristics to that of mammals and were able to infiltrate various tissues and were transplantable into syngenic animals. Interestingly, since conditional expression of the kRASG12D gene was under the control of the heat shock promoter, the authors showed that the gene could be activated ex vivo by heat shock. The cells could then be transplanted into immunosuppressed animals where they induced tumors .
BRAF
V600E melanoma model The mutation of the serine threonine kinase B-Raf (BRAF
V600E
) is involved in development of human melanoma. Patton et al. (2005) showed that melanocyte-specific expression of activated human BRAF V600E in zebrafish under the control of mitfa promoter leads to multiple nevi formation. When crossed with the p53-deficient zebrafish line, the overexpression of BRAF V600E led to formation of highly invasive melanomas that had molecular characteristics similar to those of humans including mitogen-activated protein kinase activation (Patton et al., 2005) . Recently, White et al. (2008) transplanted BRAF
; p53 melanoma cells into irradiated transparent adult casper mutant fish. The authors were able to monitor tumor progression and invasion into the distant tissues in the same animal for up to 1 month after transplantation using brightfield or fluorescent microscopy. These animals will greatly aid in the visualization of tumor progression and invasion in adult zebrafish transplanted with cancer cells or animals that acquired endogenous cancers. kRASG12D embryonic rhabdomyosarcoma model Langenau et al. (2007) developed a zebrafish model of a very aggressive childhood cancer, embryonic rhabdomyosarcoma (ERMS. Expression of activated kRASG12D under rag2 control led to the rapid (B50% of mosaic transgenic fish within 3 months of age) development of ERMS. The rag2 promoter drives the gene expression not only in T-and B-cell lineages but also in olfactory rosettes, sperm and skeletal musculature. Developing tumors in skeletal muscle tissue showed a high degree of local and distant invasion with tumor cells being found in various distant organs including the intestine, kidney and testes. Remarkably, the molecular pathways activated in fish RMS showed significant overlap with human RMS .
A current belief postulates that within the primary tumor only limited subsets of cells are responsible for tumor cell renewal and metastasis (cancer stem or initiating cells). Interestingly, Langenau et al. (2007) were also able to selectively label differentiated and progenitor tumor cells within the RMS tumor cell mass. They demonstrated that only the undifferentiated early muscle cell progenitors were capable of inducing tumor formation when transplanted into a recipient animal. Using this approach they were able to identify the cancer stem cell in zebrafish RMS.
Xenotransplantant models
Xenotransplantation of human cancer cells has been a major tool utilized by cancer biologists for many years. Recently, zebrafish has emerged as a new xenograft animal model for investigating human tumor cell biology. The ability to propagate human cancer cells in fish has three major advantages compared to the traditional rodent and chick xenograft models (Table 1) . First, it integrates the superior imaging qualities and power of zebrafish genetics with the extensive knowledgebase of human cancer biology and the deep tool chest of reagents developed through decades of research. Second, zebrafish harboring human cells are highly amenable to pharmacological testing, which combined with their cost effectiveness makes this animal attractive for developing new cancer therapeutics. Third, zebrafish provide a relatively simple, whole vertebrate system, to decipher the mechanism(s) of drug action in vivo (Amatruda et al., 2002; Smolowitz et al., 2002; Stern and Zon, 2003; Berghmans et al., 2005a; Parng et al., 2002; Goessling et al., 2007a; Kari et al., 2007) . These unique properties of zebrafish open the door to explore the underlying mechanisms that drive cancer progression in vertebrates and provide the means to develop promising preclinical agents and determine their mechanism of action.
Cancer cells derived from various species (mouse and human) and tissues (adenocarcinoma, fibrosarcoma, melanoma) have been introduced into both young embryos (2-5-days old post fertilization; Haldi et al., 2005; Lee et al., 2005; Topczewska et al., 2006; Nicoli et al., 2007) and juvenile 30-day-old zebrafish (Stoletov et al., 2007) . Both transplantation models have their specific benefits and limitations when it comes to understanding cancer cell behavior in a living organism (Table 1) .
A 30-day-old xenotransplantant model The transplantation of human cancer cells in 30-day-old transparent fish was developed in our laboratory to investigate the dynamics of microtumor formation and angiogenesis in live animals using multicolor highresolution confocal microscopy (Stoletov et al., 2007) . For these experiments, we used the Tg(fli1:egfp) transgenic vascular fish and a standard Nikon confocal microscope equipped with Â 10-60 long working distance objectives. This allowed us to view deep inside (200 mm) tissues the dynamics of microtumor formation and angiogenesis with unprecedented clarity. Under these conditions, detailed analysis of remodeling vessels could be observed and subcellular structures of cancer cells can be resolved including membrane protrusions and the nucleolus (Figure 2) . This model system is advantageous in that it provides a clear window to visualize mechanisms of microtumor formation, cell invasion and tumor-induced angiogenesis in a mature animal. Another advantage to using juvenile fish compared to using developing embryos is that all the major organs including the vasculature have completed development and have reached their mature pattern that is the same from animal to animal (Isogai et al., 2003) . This makes interpretation of tumor-induced vascular effects uncomplicated and eliminates concerns with the perturbation of developmental processes. Also, using juvenile fish as a host for human cancer cells more closely recapitulates the events associated with tumor-induced remodeling of the adult vasculature in cancer patients. However, a limitation is that 30-day-old fish have a functional immune system that must be chemically suppressed with dexamethasone for successful engraftment, whereas young embryos do not.
Most of our understanding of tumor-induced vascular remodeling and tumor cell vessel interactions has been obtained from static images captured from mature latestage tumors. This is mostly because small microtumors and micrometastatic lesions have proven quite difficult to detect in patients and animal models of cancer (Sahai, 2007) . Consequently, the early events that initiate vessel remodeling and angiogenesis during microtumor formation remain poorly defined. This is especially troublesome in regards to micrometastatic disease, which leads to death of most cancer patients. Currently, there are no therapeutic agents available to treat this fatal component of cancer.
Zebrafish (30-day-old) as a model to study microtumor formation and metastasis Zebrafish provide a promising new model system to study microtumor formation and to develop therapeutic Zebrafish models of human cancer K Stoletov and R Klemke agents to combat the spread of cancer. In live anesthetized Tg(fli1:egfp) transgenic vascular zebrafish, we demonstrated that small tumor cell aggregates expressing DsRed and/or CFP can be directly visualized over many days (10-14) forming small microtumors, actively invading solid tissues, and remodeling the host vasculature in the body wall surrounding the peritoneal cavity. Interestingly, in these animals, microtumor formation always occurred in the body wall tissue in close association with the intersegmental vessels. While the mechanism is not known, it may involve direct homing of the cells to the vessels and/or the microenvironment of this particular tissue may provide a growth advantage. In any case, these intravital observations demonstrate that there is significant level of interaction between the human cancer cells and the microenvironment of the host. Indeed, in most cases, we found that human cancer cell lines (HT1080, fibrosarcoma; Hep3, lung adenocarcinoma) reported to be highly invasive in other vertebrate models were also highly invasive in zebrafish, whereas low invasive cells (MDA-435, breast adenocarcinoma) did not significantly disseminate in the host tissue (Zijlstra et al., 2002) . Furthermore, human cancer cells harboring known metastatic genes like RhoC or src kinase display increased cell dissemination when transplanted into the peritoneal cavity of zebrafish. The dynamic interaction between host tissues and the tumor cell was clearly evident from time-lapse experiments and computerassisted 3D morphological measurements of invading tumor cells. This high-resolution, real-time analysis revealed extensive invadopodia formation, membrane blebbing, shedding of membrane particles and cell movement. The extensive interaction of the cancer cells with the host tissues is not that surprising as many extracellular matix proteins including collagen and fibronectin are highly conserved as are the integrin adhesion receptors that mediate these interactions (Sun et al., 2005; Mould et al., 2006; Ablooglu et al., 2007) .
Role of RhoC in tumor cell invasion
An interesting finding in this study was that cells expressing the metastatic gene RhoC invade tissues by utilizing a primitive amoeboid-type of invasion characterized by a rounded morphology and extensive membrane blebbing, whereas in the absence of RhoC these cells use a mesenchymal mode of invasion characterized by the formation of long extended invadopodia (Clark et al., 2000) . Recent work indicates that mesenchymal migration involves the release of matrix-degrading proteases and matrix digestion, whereas amoeboid migration utilizes dynamic membrane blebbing and cell contractile processes to traverse through existing openings in the surrounding matrix independent of proteases (Friedl and Bro¨cker, 2000; Wolf et al., 2003) . The bad news is that metastatic cells may be armed with both modes of invasion and that blocking one mode may not be sufficient to prevent cell dissemination since they can switch to the other mode. This suggests that to prevent cell invasion and metastasis in cancer patients it will be necessary to devise a strategy to knockout both invasive modes. In this regards, zebrafish seem ideal for unraveling mechanisms of human cancer cell invasion in vivo, and provide a novel system to develop therapeutic agents designed to block cell dissemination and microtumor formation.
Role of RhoC in tumor cell intravasation
While it is clear that cancer cells must gain access to the vasculature (intravasation) and lymphatic systems to metastasize, little is known about how this process occurs. Transparent 30-day-old Tg(fli1:egfp) transgenic zebrafish and confocal microscopy provide a unique opportunity to view this process in high-resolution detail. In our study, we specifically investigated how the metastatic gene RhoC mediates vascular remodeling and cell intravasation with the assumption that RhoC amplification would increase vessel remodeling and intravasation. Surprisingly, the RhoC MDA-435 (MDA-435, breast adenocarcinoma that overexpress RhoC) cells did not show increased ability to remodel vessels or intravasate, even though they show increased invasiveness in tissues and metastasis in mice (Hakem et al., 2005) . In fact, the RhoC cells randomly scattered throughout the fish tissues, but did not tightly cluster around and remodel the intersegmental vessels, which is in contrast to the low metastatic control cells. This was surprising as many highly aggressive tumors display increased vascular remodeling and angiogenesis that contributes to the metastatic process (Naumov et al., 2006) . How then does RhoC facilitate cancer cell metastasis?
Role of VEGF in RhoC-induced tumor cell intravasation Since RhoC is not involved in tumorigenesis per se, we reasoned that RhoC may be a late-activating gene that facilitates intravasation after the angiogenic switch has been triggered in advanced-stage tumors (Hakem et al., 2005) . To mimic the angiogenic switch in zebrafish, we engineered the MDA-435-RhoC cells to secrete human vascular endothelial growth factor (VEGF) and injected these cells into the peritoneal cavity of 30-day-old animals. Intravital imaging of the tumor cell vasculature interface in these animals revealed the following important information. First, human VEGF induced a classic angiogenic response by the host characterized by a tortuous, disorganized network of newly formed blood vessels with enlarged vessel lumens, irregular vessel wall thickness and increased leakiness due to vessel permeabilization (Jain, 2002; Fukumura and Jain, 2007) . These vascular changes could be reversed by treatment of animals with the vascular endothelial growth factor receptor (VEGFR) kinase inhibitor SU5416 (Stoletov et al., 2007) . Second, new vessels appeared within 3 days making this the most rapid and robust tumor-induced angiogenesis model to date. Third, optical sectioning and computer assisted 3D modeling of the neovasculature revealed small regions of the vessel wall that were extremely thin or not present at all. Upon 3D reconstruction, these areas appeared as 1-3 mm vascular openings.
Finally and most importantly, in many cases MDARhoC cells were no longer observed to scatter throughout the tissue, but rather were found to localize at the injection site and to directly dock onto the vascular openings where they protruded large invadopodia well into the vessel lumen. The low metastatic control cells without RhoC also docked onto the vessel openings, but they did not protrude large membrane structures into the lumen. These findings suggested that RhoC increases the ability of human cancer cells to intravasate through formation of specialized invadopodia capable of protruding through vascular openings. These findings were also corroborated in the chick CAM model where RhoC expression was also found to significantly increase cell intravasation in a VEGF-dependent manner. Together the findings indicate that RhoC and VEGF work cooperatively to facilitate tumor cell intravasation through regulation of the actin-myosin cytoskeleton and vascular remodeling. This work highlights the use of translucent zebrafish as model system to uncover mechanisms of tumor progression and cancer cell dissemination in vivo. In the future, it will be important to identify the molecular mechanisms that facilitate vascular pore formation and tumor cell docking on the vessel surface, and whether the cooperative interactions between metastatic gene expression and vascular remodeling are specific to VEGF and RhoC or whether these events also occur in response to other angiogenic agents and metastatic genes.
Early embryo xenotransplantant model
Transplantation of human cancer cells into early-stage (6-48 h post-fertilization) zebrafish embryos has also revealed important information about cancer biology as reported by several groups (Haldi et al., 2005; Lee et al., 2005; Topczewska et al., 2006; Nicoli et al., 2007) . The major advantage of this model is that the immune system is still immature that permits human tumor cell engraftment. It is also possible to silence host genes using morpholinos and to perform immunostaining and in situ hybridization on whole embryos.
Early embryo model: tumor cell plasticity Using young embryos, Lee et al. (2005) found that transplanted human melanoma cells were highly invasive and randomly scatter within the embryonic tissue, whereas primary melanocytes were often integrated normally with the developing skin. When examined for expression of melanocyte differentiation factors in vivo, aggressive melanoma cells were found to remain in a dedifferentiated state expressing both mesenchymal and epithelial markers. The authors concluded that aggressive human melanoma cells remain in a 'plastic' undifferentiated state, and are unable to properly respond to differentiation and migratory cues from the host environment, while differentiated melanocytes presumably can respond bi-directionally to these signals.
Interestingly, in a follow up study Lee et al. found that introduction of human melanoma cells into young zebrafish embryos could redirect normal embryonic development. Transplantation of aggressive human melanoma cells (C8161) into the animal pole promoted formation of a secondary embryonic axis while the less aggressive (C81-61) cells did not (Topczewska et al., 2006) . The highly aggressive melanoma cells were found to secrete Nodal, a potent embryonic morphogen and member of the transforming growth factor-b superfamily. Consequently, the authors showed that Nodal expression correlates with human melanoma progression and inhibition of Nodal signaling impairs anchorage-independent growth and tumor formation in nude mice. Based on this work, Nodal has emerged as a promising diagnostic marker of disease progression and a possible target for development of an anticancer therapeutic. This powerful approach brings together the ability to investigate human cancer progression and developmental biology in a highly tractable animal system, which provides a promising mechanism to elucidate the complex developmental programs that control cancer cell renewal and differentiation and the epigenetic influences that modulate these cells.
Early embryo model: human tumor cell-induced angiogenesis and the role of VE-cadherin Haldi et al. (2005) injected several human cell lines (WM-266-4 metastatic melanoma, FG pancreatic carcinoma and SW620 colon carcinoma) into the yolk sac of 2-day-old zebrafish embryos. Upon injection into the yolk sac these tumor cell lines survived, proliferated and migrated for up to a week, while normal human foreskin fibroblasts did not. In about half of the animals, the injected cells formed tumor-like masses primarily in the regions surrounding the intestine, pancreas and liver. Sectioning and immunostaining of the tumor cell masses using a specific antibody that recognizes activated zebrafish endothelial and angioblast cells revealed that endothelial cells selectively associate with tumor cell masses and form vessel-like structures. This early study demonstrated the feasibility of using young zebrafish embryos for human cancer research and laid the foundation for future work to develop efficient throughput methods for the identification of therapeutic agents that impact human cancer. Nicoli et al. (2007) showed that when injected into 2-day-old zebrafish embryos human and murine tumorigenic cell lines (mouse aortic endothelial, MDA-MB-435 human adenocarcinoma and B16 human melanoma) induced a robust angiogenic response in association with the surrounding intestinal vascular plexus. This response was significantly increased when the injected cancer cells were genetically engineered to express human FGF2 or VEGF growth factors. The forming vessels expressed multiple markers previously associated with angiogenic vessels in mammals including Fli-1, VEGFR2/KDR and VE-cadherin. FGF2-and VEGF-induced vessel formation was specific to FGF2 or VEGF receptors since embryo exposure to chemical inhibitors that target these receptors (SU5402 and SU5416, respectively) potently abrogated the angiogenic response.
The researchers also investigate the role of VEcadherin in mediating tumor cell-induced angiogenesis since it has been previously linked to tumor angiogenesis in mice (Wallez et al., 2006) . VE-cadherin is a cell-cell adhesion molecule that mediates endothelial cell survival, proliferation and vessel tube formation. In zebrafish, the VE-cadhern/Cdh5 gene is widely expressed in angioblasts and the developing vascular system and into adulthood (Larson et al., 2004) . Strikingly, this group showed that morpholino knockdown of VE-cadherin expression selectively prevented tumor cell-induced angiogenesis by FGF2, but not normal vessel development including formation of the intersegmental and subintestinal vessels. These findings are surprising in light of the fact that VE-cadherin null mice display several vascular defects in vessel assembly that cause embryonic lethality at day 9.5 (Carmeliet et al., 1999) . The apparent discrepancy in these studies may be due to differences in the vascular programs utilized by fish and mammals. It is also possible that tumor-induced vessel formation in zebrafish may be uniquely sensitive to perturbation of VE-cadherin expression or that the same programs that drive tumor-induced angiogenesis are different from those that drive developmental vasculogenesis. Although the level of VE-cadherin expression was not examined in situ in this study, the morpholino knockdown of a gene product is rarely complete. The possibility remains that the residual VE-cadherin is sufficient to support developmental vasculogenesis, but not tumor-induced neovascularization. In any case, this work highlights the power of zebrafish embryos and morpholino technology to dissect the molecular differences that give rise to normal and tumor-associated vessels. The caveat is that it is not clear whether human cells can initiate new vessel growth or whether it results from the redirection of developing vessels already in the process of forming. The developing vessels may respond differently to tumor-induced angiogenic factors compared to mature, fully developed vessels. The 30-day-old fish seem better suited to address this type of question since the vasculature has obtained its final form.
Future directions
Within the past several years, zebrafish has shown great promise to become a powerful animal model to study cancer progression. Despite the significant progress additional work is necessary to fully explore how closely these processes parallel mammalian cancer mechanisms and how well they translate to human disease. This will require detailed comparative studies among transgenic and xenograft zebrafish and mouse models of cancer and their relevance to the disease. The experimental results then need to be carefully interrogated for their relevance to human disease. Only when zebrafish has undergone this degree of scrutiny will its full potential be realized and its acceptance widely embraced by the cancer research community.
If zebrafish are going to contribute significantly to our understanding of cancer, then noninvasive and quantitative methodologies for imaging tumor formation and distant metastases will have to be developed, especially in regards to monitoring cancer progression in adult animals. It may be possible to reconfigure the various tumor detection methods established in mice for use on small zebrafish as was the case with ultrasound technology. The development of imaging technology should also include fluorescence protein-based approaches and quantitative software capable of measuring cancer progression over many days and months in live fish. The recent development of a transparent adult zebrafish line (casper) similar to the transparent Medaka TRA line will undoubtedly improve imaging of adult zebrafish tumors and their metastases (Wakamatsu et al., 2001; White et al., 2008) . Continued effort needs to be put into developing environmentally controlled systems that facilitate prolonged time-lapse imaging of live animals for low-and high-resolution applications. Finally, the reengineering of existing high throughput imaging systems and liquid handling instrumentation for use with zebrafish embryos would be extremely valuable for gene and chemical screening studies (Parng et al., 2002) .
While several groups have reported that zebrafish tumors can grow to a significant size and invade surrounding tissues, the ability of these cells to metastasize has not been formally demonstrated. In some cases invasive RMS or BRAF V600E melanoma cells were found at significant distances from the primary tumor site White et al., 2008) . It remains to be determined whether the spread of cancer under these conditions was due to cell dissemination through the vasculature/lymphatics or resulted from cell invasion of the tissues. In our study, we showed that invasive human tumor cells can readily penetrate the remodeling blood vessel wall, which is a critical step in the metastatic process. We have also observed in preliminary studies that human cancer cells, when injected directly into the vasculature of 2-day-old zebrafish embryos, lodge in small vessels in various organs and extravasate into the surrounding tissue (Stoletov et al., 2007;  Figure 3) . Haldi et al. (2005) using human melanoma cells reported similar results. While these initial results are encouraging, additional work needs to be done to confirm that fish and human cancer cells metastasize using the typical vascular and lymphatic routes, and that similar mechanisms known to drive these processes in mammals also operate in zebrafish. If this turns out to be the case, then zebrafish could be a tractable model to address this troublesome problem that has faced cancer researchers for many years.
It is well recognized that the vasculature of the tumor differs significantly in molecular and morphological characteristics compared to the normal blood system (Fukumura and Jain, 2007) . These abnormalities are being exploited as a potential means to direct antitumor therapies. While tumors growing in zebrafish have been reported to be vascularized, it is not yet clear if the vessels display similar morphological and biochemical markers as mammals. We found that human tumor cells secreting VEGF induce new vessels in zebrafish with a tortuous, irregular shape, altered thickness of the vessel wall and increased permeability, all of which typify the events observed in mammalian tumor development. However, additional work is necessary to determine if these vessels are expressing similar vascular markers established in mammals and whether the actual process of vessel formation is governed by the same mechanisms that drive tumorinduced angiogenesis in mammals. Nevertheless, this is a worthy pursuit since zebrafish is the only whole animal model with the potential for cost-effective, large-scale screens, to identify chemical or genetic modifiers that alter tumor dissemination and/or angiogenesis (Parng et al., 2002) . 
Zebrafish models of human cancer K Stoletov and R Klemke
Xenotransplantation of human cells into immunocompromised mouse strains has greatly aided cancer researchers over the years. Currently, tumor cell transplantation in zebrafish requires chemical immunosuppression of the animals or tumor cell transplantation of syngenic zebrafish cell lines. The development of zebrafish with an impaired immune system similar to that of severe combined immunodeficiency or nude mice will allow efficient transplantation of mammalian and zebrafish cell lines into young and adult animals. However, while a large supply of mammalian cancer cell lines exists, there are no zebrafish cancer cell lines permanently established in culture. Consequently, significant effort needs to be put into developing fish cancer cell lines harboring known oncogenes relevant to human cancer. This will open the door for performing functional cell-based studies, prescreening genetic and chemical modifiers of cancer, and the development of antibodies to zebrafish proteins that are sorely needed.
Finally, there is a continued need to develop transgenic animals that develop cancer in response to tissue-specific expression of known oncogenes fused with marker proteins for imaging purposes and inducible promoter systems for controlled expression. These animals should then be crossed with transgenic animals that report changes in the blood vessel state and tumorimmune cell interactions. These animals would greatly facilitate real-time imaging of the tumor-induced vascular remodeling events and the dynamic immune cell movements that occur in the tumor microenvironment. Many transgenic lines have already been developed including T cell, macrophage and neutrophil reporter animals (Langenau et al., 2004; Mathias et al., 2006; Hall et al., 2007) .
In summary, zebrafish is a major catch for cancer researchers offering a number of unique advantages for investigating the mechanisms that drive cancer formation and progression. At the top of the list are its optical clarity, genetic tractability and amenability to pharmacological testing. It is no wonder that cancer researchers are taking notice as these attributes provide new avenues for significant discoveries and an affordable whole animal system for therapeutic development. Now that zebrafish are clearly in the eyes of cancer researchers it will be fascinating to witness the evolution of zebrafish cancer research as it fulfills its many promises in the upcoming years.
